Hikma Pharmaceuticals PLC
Results of 2023 Annual General Meeting
LONDON, 28 April 2023 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN and virtually on 28 April 2023 commenced at 11 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 20 were passed as ordinary resolutions and Resolutions and 21 to 24 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 16 March 2023) is set out below. The number of Ordinary Shares in issue on 27 April 2023 was 233,821,373. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 220,988,140.
|
Resolution |
Votes For |
% |
Votes Against |
% |
Total Cast |
Withheld |
|
1. To receive the 2022 report and accounts |
173,404,465 |
99.99 |
18,525 |
0.01 |
173,422,990 |
1,486,671 |
|
2. To approve a final dividend of 37 cents per share |
174,904,572 |
100.00 |
3,407 |
0.00 |
174,907,979 |
1,682 |
|
3. To re-appoint PricewaterhouseCoopers LLP as Auditor |
173,901,259 |
99.43 |
1,004,451 |
0.57 |
174,905,710 |
3,951 |
|
4. To authorise the Audit Committee to determine the remuneration of the Auditor |
174,902,468 |
100.00 |
4,247 |
0.00 |
174,906,715 |
2,946 |
|
5. To elect Laura Balan as a Director of the Company |
174,560,635 |
99.80 |
345,653 |
0.20 |
174,906,288 |
3,373 |
|
6. To elect Victoria Hull as a Director |
172,985,379 |
98.90 |
1,920,959 |
1.10 |
174,906,338 |
3,322 |
|
7. To elect Dr Deneen Vojta as a Director |
174,145,610 |
99.57 |
759,059 |
0.43 |
174,904,669 |
4,992 |
|
8. To re-elect Said Darwazah as a Director |
167,417,879 |
95.79 |
7,363,833 |
4.21 |
174,781,712 |
127,949 |
|
9. To re-elect Mazen Darwazah as a Director |
166,197,026 |
95.09 |
8,584,687 |
4.91 |
174,781,713 |
127,948 |
|
10. To re-elect Patrick Butler as a Director |
169,789,166 |
97.08 |
5,115,966 |
2.92 |
174,905,132 |
4,529 |
|
11.To re-elect Ali Al-Husry as a Director |
173,667,423 |
99.36 |
1,114,623 |
0.64 |
174,782,046 |
127,615 |
|
12. To re-elect John Castellani as a Director |
174,135,021 |
99.56 |
770,111 |
0.44 |
174,905,132 |
4,529 |
|
13. To re-elect Nina Henderson as a Director |
172,945,073 |
98.88 |
1,961,390 |
1.12 |
174,906,463 |
3,198 |
|
14. To re-elect Cynthia Flowers as a Director |
174,560,963 |
99.80 |
345,325 |
0.20 |
174,906,288 |
3,373 |
|
15. To re-elect Douglas Hurt as a Director |
174,135,291 |
99.56 |
769,811 |
0.44 |
174,905,102 |
4,559 |
|
16. To receive and approve the annual report on Remuneration |
169,944,824 |
97.16 |
4,959,681 |
2.84 |
174,904,505 |
5,145 |
|
17. To approve the Directors' Remuneration Policy |
171,820,411 |
98.24 |
3,085,011 |
1.76 |
174,905,422 |
4,239 |
|
18. To authorise the Directors to allot shares and grant rights to subscribe for shares |
169,738,766 |
97.05 |
5,168,220 |
2.95 |
174,906,986 |
2,674 |
|
19. To approve the Long-Term Incentive Plan 2023 |
172,742,090 |
98.76 |
2,164,458 |
1.24 |
174,906,548 |
3,113 |
|
20. To approve the Deferred Bonus Plan 2023 |
173,885,322 |
99.42 |
1,021,749 |
0.58 |
174,907,071 |
2,590 |
|
21. To authorise the disapplication of pre-emption rights (General) |
166,689,167 |
95.30 |
8,217,162 |
4.70 |
174,906,329 |
3,331 |
|
22. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment) |
159,504,839 |
91.19 |
15,401,490 |
8.81 |
174,906,329 |
3,331 |
|
23. To authorise the Company to purchase Ordinary Shares |
173,797,944 |
99.42 |
1,018,079 |
0.58 |
174,816,023 |
93,638 |
|
24. To authorise the Company to hold general meetings on not less than 14 clear days' notice |
169,319,647 |
96.81 |
5,588,186 |
3.19 |
174,907,833 |
1,828 |
Senior Independent Director
At the conclusion of the AGM, as reported in our 2022 Annual Report, Patrick Butler stepped down as Senior Independent Director, Chair of the Nomination and Governance Committee and as a member of the Audit Committee and Remuneration Committee. Patrick Butler will remain on the Board as a non-independent Non-Executive Director for one further year, stepping down no later than the 2024 AGM. Victoria Hull was appointed as Senior Independent Director and Chair of the Nomination and Governance Committee.
Declaration of final dividend
The dividend of 37 cents per share will be paid on 5 May 2023 to shareholders on the register on 24 March 2023. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2532 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.71JD.
- ENDS -
Enquiries:
|
Hikma Pharmaceuticals PLC |
|
|
Hussein Arkhagha Chief Counsel and Company Secretary
|
+44 20 7399 2670 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
